Bipolar Disorder  >>  Vraylar (cariprazine)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
NCT01058096: Safety and Efficacy of Cariprazine for Mania

Completed
3
323
US, RoW
Cariprazine, Placebo
Forest Laboratories, Gedeon Richter Ltd.
Bipolar Disorder, Mania
07/11
07/11
NCT01058668: Safety and Efficacy of Cariprazine for Bipolar I Disorder

Completed
3
497
US, Europe, RoW
Cariprazine, Placebo
Forest Laboratories, Gedeon Richter Ltd.
Mania, Bipolar I Disorder
12/11
12/11
NCT01059539 / 2009-016041-25: Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder

Completed
3
403
US, Europe
Cariprazine, RGH-188
Forest Laboratories, Gedeon Richter Ltd.
Bipolar I Disorder
02/12
02/12
NCT02670551 / 2016-000757-13: Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression

Checkmark RGH-MD-54 study for bipolar I depression
Dec 2017 - Dec 2017: RGH-MD-54 study for bipolar I depression
Completed
3
488
US, Europe
Cariprazine, VRAYLAR®, Placebo
Forest Laboratories
Bipolar Disorder, Depression
07/17
07/17
NCT02670538 / 2016-000756-98: Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

Checkmark Efficacy data from RGH-MD-53 study
Apr 2018 - Apr 2018: Efficacy data from RGH-MD-53 study
Completed
3
493
US, Europe, RoW
Cariprazine, Vraylar, Placebo
Forest Laboratories
Bipolar Disorder, Depression
01/18
01/18
NCT03573297 / 2017-000803-25: A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

Completed
3
901
Europe, US, RoW
Cariprazine, Placebo
AbbVie
Bipolar I Disorder, Mania, Depression
09/22
09/22
NCT04777357: A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Recruiting
3
380
US, RoW
Cariprazine, Vraylar, Placebo
AbbVie
Depression, Bipolar I Disorder
03/27
03/27
NCT04578756: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Recruiting
3
280
US
Cariprazine Flexible Dose
AbbVie
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
09/25
09/25

Download Options